Keros Therapeutics (NASDAQ:KROS) Downgraded by Cantor Fitzgerald to Neutral

Keros Therapeutics (NASDAQ:KROS) was downgraded by Cantor Fitzgerald from an “overweight” rating to a “neutral” rating in a report released on Tuesday,Briefing.com Automated Import reports.

Other research analysts have also recently issued reports about the company. Jefferies Financial Group started coverage on Keros Therapeutics in a research report on Tuesday, November 5th. They issued a “buy” rating on the stock. HC Wainwright dropped their price objective on shares of Keros Therapeutics from $100.00 to $47.00 and set a “buy” rating on the stock in a report on Friday, December 13th. Piper Sandler reduced their target price on shares of Keros Therapeutics from $40.00 to $15.00 and set an “overweight” rating for the company in a report on Friday. Truist Financial dropped their price target on shares of Keros Therapeutics from $100.00 to $43.00 and set a “buy” rating on the stock in a research note on Monday, December 23rd. Finally, Wedbush lowered Keros Therapeutics from an “outperform” rating to a “neutral” rating and reduced their price objective for the stock from $47.00 to $15.00 in a research note on Friday. Six equities research analysts have rated the stock with a hold rating and eight have issued a buy rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $52.56.

Keros Therapeutics Trading Up 3.2 %

Keros Therapeutics stock opened at $10.86 on Tuesday. Keros Therapeutics has a 12 month low of $9.77 and a 12 month high of $73.00. The stock has a fifty day simple moving average of $35.23 and a two-hundred day simple moving average of $46.97. The firm has a market cap of $439.94 million, a price-to-earnings ratio of -2.08 and a beta of 1.43.

Keros Therapeutics (NASDAQ:KROS) last posted its earnings results on Wednesday, November 6th. The company reported ($1.41) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.28) by ($0.13). Keros Therapeutics had a negative net margin of 27,890.94% and a negative return on equity of 41.74%. The company had revenue of $0.39 million for the quarter. During the same quarter in the prior year, the company earned ($1.33) EPS. The business’s revenue for the quarter was up 4750.0% on a year-over-year basis. On average, equities research analysts forecast that Keros Therapeutics will post -4.74 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of the business. Renaissance Technologies LLC purchased a new stake in Keros Therapeutics in the second quarter worth $654,000. XTX Topco Ltd purchased a new position in Keros Therapeutics in the 2nd quarter worth about $228,000. Point72 DIFC Ltd bought a new stake in Keros Therapeutics during the 2nd quarter valued at about $802,000. Squarepoint Ops LLC purchased a new stake in Keros Therapeutics in the 2nd quarter valued at about $906,000. Finally, Point72 Asia Singapore Pte. Ltd. purchased a new stake in Keros Therapeutics in the 2nd quarter valued at about $128,000. Institutional investors own 71.56% of the company’s stock.

Keros Therapeutics Company Profile

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.